drugset / Trial / NCT05082545
Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is Phase 1 study FIH to check "Dose Escalation, Dose expansion and Indication expansion". This study is AUSTRALIA only study.
Timeline
- Start
- 2021-11-23
- Primary completion
- 2023-07-17
- Completion
- 2024-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | SHR-2002 | Unknown | — | — |